# Corona Remedies share price today (Corona Remedies Ltd, NSE: CORONA)

> Corona Remedies share price today: ₹2,405.80 at the NSE close on 4 November 2026, up 75.1% in a year. Corona Remedies (NSE: CORONA) is worth ₹14,711 crore, trades at a P/E of 66.8 and has closed between ₹1,347.70 and ₹2,405.80 over the past 52 weeks. > Corona Remedies Ltd's share price has risen faster than its earnings: +75.1% in a year, against +23.9% for earnings per share. CORONA · Pharma - Formulators · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/corona-remedies-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹2,405.80 (+75.1% in a year)
- P/E: 66.8× (higher than 100% of the last 11 months)
- Revenue (Sep 2026): ₹441 Cr (+22.2% on a year ago)
- Profit (Sep 2026): ₹60.0 Cr (+15.4% on a year ago)
- Operating margin: 22.0% (flat on a year ago)
- ROCE: 33%, FY26
- ROIC: 25.7%, against a 12.0% cost of capital: +13.7 points
- Profit that came in as cash: 136%, last 3 years

The main question: the share price moved +75.1% in a year while yearly earnings per share moved +23.9%. The difference came from the market paying a higher multiple. ## What is the Corona Remedies share price today? Corona Remedies Ltd's share price was ₹2,405.80 at the close on 4 November 2026. It has been rising for 38 weeks. That is 28.2% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 3 weeks in a row. Since its first close in our records, on 19 December 2025, it has traded between ₹1,348 and ₹2,406, and at that close it was at the high of that range. Over the last 11 months the share price moved +75% while the NIFTY 500 moved −8%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Corona Remedies this quarter? Three changes stood out: indian funds and insurers (DIIs) raised their stake for 3 quarters in a row, foreign funds (FIIs) raised their stake for 3 quarters in a row and revenue up on a year earlier for 5 quarters in a row (every quarter we can compare). 1. Indian funds and insurers (DIIs) raised their stake for 3 quarters in a row From 6.8% to 16.4% of the company by the September 2026 quarter. 2. Foreign funds (FIIs) raised their stake for 3 quarters in a row From 1.8% to 4.2% of the company by the September 2026 quarter. 3. Revenue up on a year earlier for 5 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹441 crore, +22.2% on a year earlier. ## What are Corona Remedies' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Corona Remedies reported revenue of ₹441 crore, up 22.2% from ₹361 crore a year earlier, and a profit of ₹60.0 crore, up 15.4% from ₹52.0 crore. ### Corona Remedies results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹441 crore | ₹361 crore | +22.2% |
| Profit | ₹60.0 crore | ₹52.0 crore | +15.4% |
| Earnings per share | ₹9.86 | ₹8.55 | +15.3% |
| Operating margin | 22.0% | 22.0% | 0.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 3 August 2026, about April to June 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Corona Remedies share price history? Corona Remedies closed at ₹2,405.80 on 4 November 2026, up 75.1% from ₹1,374.30 a year earlier (19 December 2025). Its highest weekly close since December 2025 was ₹2,405.80 on 4 November 2026. ### Corona Remedies share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹2,149.60 | +11.9% |
| 1 month ago · 1 Oct 2026 | ₹2,029.40 | +18.5% |
| 6 months ago · 8 May 2026 | ₹1,712.30 | +40.5% |
| 1 year ago · 19 Dec 2025 | ₹1,374.30 | +75.1% |
| Earliest weekly close in our records · 19 Dec 2025 | ₹1,374.30 | +75.1% |
| Highest weekly close since December 2025 · 4 Nov 2026 | ₹2,405.80 | 0.0% |
| Lowest weekly close since December 2025 · 26 Dec 2025 | ₹1,364.70 | +76.3% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (54 weekly closes from 19 December 2025 to 4 November 2026.)

## What is the latest news on Corona Remedies? 4 Nov 2026: Corona Remedies closed at ₹2,405.80, up 11.9% on the week and up 18.5% on the month. Results for July to September 2026: Revenue up 22.2% and profit up 15.4% on a year earlier. ### Earlier

- 3 Aug 2026: Corona Remedies held its results call for April to June 2026. Management guided: FY27 organic revenue growth 15.0% and profit growth 20.0%. - 19 Jun 2026: ex-date for a dividend of ₹10 a share. ## What dividend does Corona Remedies pay? Corona Remedies paid ₹10 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.42% at the ₹2,405.80 close on 4 November 2026. The last was a dividend of ₹10 a share, ex-date 19 June 2026. ### Corona Remedies dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 19 Jun 2026 | ₹10 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 0 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Corona Remedies Ltd paid out 33% of its profit as dividends in FY26, and it paid a dividend in each of its last 4 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Corona Remedies management say on the latest results call? On the call for April to June 2026, held on 3 August 2026, Corona Remedies' management guided: FY27 organic revenue growth 15.0% and profit growth 20.0%. > “To strengthen our philosophy of "think hormone, think CORONA," which is somewhat complex in nature and where very few plants are focusing on hormones, the facility will help us in India as well, and it will also start gaining recognition in the international market.”
> Nirav Mehta, on the call for April to June 2026

### What management guided

- FY27 inorganic revenue contribution of 1.5%-2.0%, resulting in about 17.0% total revenue growth. - Wokadine portfolio growth 25.0% over the coming 3 years, doubling internal revenue from ₹20 crore to ₹40 crore. - No FY27 medical-representative additions; thereafter additions of 6.0%-8.0% annually, approximately 200-250 people. - Hormone facility asset turnover below 1.0 in FY27, moving through 2.0 toward 3.0 over the next 3 years; owned and outsourced manufacturing mix about 60.0%/40.0% in FY27. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/58986/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 3 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What to watch in Corona Remedies' next results? When Corona Remedies reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Raw-material pressure and gross-margin resilience - test whether cost offsets absorb the flagged geopolitical input shock. - What to check (from the call)
- Raw-material pressure and gross-margin resilience - test whether cost offsets absorb the flagged geopolitical input shock. - Wokadine supply-chain integration - check whether sales acceleration follows the non-representative opening quarter. - Hormone facility absorption - check domestic utilization and operating-cost burden after commercialization. - IVF task force - check for the fuller traction update management deferred. ## Which stock lists is Corona Remedies on? Corona Remedies is on 3 of our India lists: Momentum stocks, Small & mid cap stocks and Pharma stocks. - [Momentum stocks Market cap cr: 14713.924730182363](https://www.sectoralpha.in/momentum-stocks-india)
- [Small & mid cap stocks Size rank in India: 481](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 14713.924730182363](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Corona Remedies profitable? Corona Remedies Ltd earned ₹60.0 Cr of net profit in the Sep 2026 quarter, +15.4% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹185 Cr. Over 3 years profit has grown 29.6% a year on average. That is 13.6% of the quarter's revenue. The same quarter a year earlier earned ₹52.0 Cr. For the full year, FY26 profit was ₹185 Cr (+24.2% on the year before). Why profit moved: revenue changed +22.2% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +19.4% and revenue +19.7%. Profit and revenue are moving at about the same pace. ## How much revenue does Corona Remedies make, and is it growing? Corona Remedies Ltd reported ₹441 Cr of revenue in the Sep 2026 quarter, +22.2% on the same quarter a year earlier. That is the 7th quarter in a row with growth on the year before. Over 3 years it has grown 16.6% a year on average. The last full year, FY26, came in at ₹1,403 Cr. The last four reported quarters add to ₹1,558 Cr. FY26 revenue was ₹1,403 Cr, +17.3% on the year before. Recent pace: the last four quarters grew +19.7% on average, against 16.6% a year over the longer run, so this year is growing faster than its own long-run rate. ## How much of every ₹100 of sales does Corona Remedies keep? Corona Remedies Ltd's operating margin was 22.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Across 4 years it has been between 14.0% and 21.0%. The latest quarter is above every full year in that period. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed +0.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Corona Remedies' profit turning into cash? Over the last 3 years, 136% of Corona Remedies Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹229 Cr of operating cash against ₹185 Cr of profit. After ₹179 Cr of spending on assets, ₹50.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 136% of profit came in as cash: the cash cycle got 48 days shorter between FY23 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 5.3× depreciation over three years. The next section checks what that spending is building. ## Where does Corona Remedies' cash go? Corona Remedies Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 7 days in FY26, down from 55 days in FY23. It spent ₹550 Cr on assets over the last 3 years. Customers take 38 days to pay, and stock sits for 175 days on average. At FY26 sales of ₹1,403 Cr, each day of that cycle ties up about ₹3.8 Cr, so roughly ₹27.0 Cr is tied up in the business at any time. FY26: customers took 38 days to pay and stock sat for 175 days, about 5.8 months of sales sitting as stock, for a full cycle of 7 days, shorter than FY23's 55. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 175 days. Customers pay about 38 days after that. Suppliers are paid at 206 days. Together that makes the 7-day cycle. Spending on assets: ₹550 Cr over the last 3 years, against ₹103 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹143 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Corona Remedies' P/E ratio, and how does it compare with its own history? Corona Remedies Ltd's P/E is 66.8×, about the highest it has ever been. Its usual P/E (the middle reading) is 57.8×, over 11 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹33.85. Why the multiple is where it is: over the past year earnings per share moved +23.9% while the price moved +75.1%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Corona Remedies business getting better or worse? Corona Remedies Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 7 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Corona Remedies earn on its capital? Corona Remedies Ltd earned a ROCE of 33% in FY26. That is up from a low of 25% in FY24. Its return on capital used (ROIC) is 13.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 13.2% net margin and 1.16× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 13.2% net margin × 1.16× asset turnover × 1.61× leverage (assets divided by equity) ≈ 24.7% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 25.7% − 12.0% = +13.7 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. ## Does Corona Remedies have too much debt? Corona Remedies Ltd has total debt of ₹165 Cr against shareholder equity of ₹747 Cr as of Jun 2026, so its debt is 0.22× its equity, which is very little. Year by year, that ratio went from 0.33 in FY24 to 0.22 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Corona Remedies shareholding pattern? No group of Corona Remedies Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. ## How far is Corona Remedies from balance-sheet trouble? For Corona Remedies Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Corona Remedies rank in its industry? 62.3 out of 100, rank 12 of 44 in Pharma - Formulators, with 73% of the evidence available. Corona Remedies Ltd scores 62.3 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 12. There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. The three scored parts add up to the total exactly: 28.5 + 25.2 + 8.6 = 62.3 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Corona Remedies compared with? Corona Remedies ranks 12 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 62.3 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.0/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18 + 11 + 12.3 = 71.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.5/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.5 + 9.1 + 18.6 = 70.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.4 + 11.2 + 8.6 = 69.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 7.1 + 10.5 = 69 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 66.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 20.4 + 16.1 + 2 = 66.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 8. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Most evidence points up · 74% evidence 65.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 18.3/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 18.3 + 6.3 + 11.9 = 65.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.7 out of 100 Growth Capital Valuation Relative
12. Corona Remedies Ltd this page CORONA · turning · Evidence leans up · 73% evidence 62.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/43.75 · Revenue 19.9% · Profit 17.7% · Operating margin change 0 points · 100% evidence Capital efficiency 25.2/31.25 · ROCE 33.3% · Operating margin 22% · 100% evidence Valuation 8.6/25 · P/E 59.7× · PEG 2.24 · 65% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 28.5 + 25.2 + 8.6 = 62.3 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 59.5 out of 100 Growth Capital Valuation Relative
16. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
17. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.0 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.9 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 47.9 out of 100 Growth Capital Valuation Relative
24. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.6 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 45.9 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.4 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 40.7 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.4 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 33.6 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Corona Remedies in size? Corona Remedies is the 23rd largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Alembic Pharmaceuticals, Natco Pharma and Marksans Pharma. Just below it: Akums Drugs & Pharmaceuticals, Strides Pharma Science and Suven Life Sciences. ### Pharma - Formulators companies close in size

1. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) ₹15,683 crore
2. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) ₹15,348 crore
3. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) ₹13,876 crore
4. Corona Remedies Ltd ₹13,147 crore
5. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) ₹11,517 crore
6. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) ₹9,851 crore
7. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) ₹7,314 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Punjab & Sind Bank](https://www.sectoralpha.in/stocks/punjab-sind-bank) ₹13,240 crore · Banks - PSU
2. [BASF India Ltd](https://www.sectoralpha.in/stocks/basf-india-ltd) ₹13,198 crore · Chemicals - Organic
3. Corona Remedies Ltd ₹13,147 crore
4. [Gujarat Mineral Development Corporation Ltd](https://www.sectoralpha.in/stocks/gujarat-mineral-development-corporation-ltd) ₹13,090 crore · Mining/Minerals
5. [Fractal Analytics Ltd](https://www.sectoralpha.in/stocks/fractal-analytics-ltd) ₹13,059 crore · IT Enabled Services/Business Process Outsourcing

## What else do people ask about Corona Remedies? ### What is Corona Remedies's share price today? Corona Remedies Ltd's share price is ₹2,405.80, +75.1% over the past year. The whole company is worth ₹14,711 Cr on the market. It is at its highest price of the past 52 weeks (range ₹1,348 to ₹2,406), 28.2% above its 200-day average. The price has been rising for 38 weeks (as of 4 November 2026). ### What were Corona Remedies's latest quarterly results? Corona Remedies Ltd reported revenue of ₹441 Cr and net profit of ₹60.0 Cr for the Sep 2026 quarter. Revenue rose 22.2% and profit rose 15.4% compared with a year earlier. Earnings per share were ₹9.86. The operating margin was 22.0%, 0.0 percentage points higher than a year earlier (as of 4 November 2026). ### What is Corona Remedies's market cap? Corona Remedies Ltd's market capitalisation is ₹14,711 Cr at a share price of ₹2,405.80. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Corona Remedies performing? Corona Remedies Ltd's share price has been rising for 38 weeks. In its latest quarter, revenue rose 22.2% and profit rose 15.4% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 3 weeks running (as of 4 November 2026). ### Is Corona Remedies in an uptrend? Yes, the price has been rising for 38 weeks (stage 2 of 4), 28.2% above its 200-day average, and at its highest point of the past 52 weeks. A share price tends to move through four phases: moving sideways, rising, stalling and falling (as of 4 November 2026). ### Will Corona Remedies's share price go up? This page does not forecast Corona Remedies Ltd's share price. What it shows instead: the share price is ₹2,405.80, and it has been rising for 38 weeks. Its P/E of 66.8× is higher than 100% of its own last 1 years (as of 4 November 2026). ### Who owns Corona Remedies? Promoters own 69.0% of Corona Remedies Ltd, foreign institutions 4.2%, domestic institutions 16.4% and the public 10.3% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 4 November 2026). ### Where is Corona Remedies in its business cycle? Corona Remedies Ltd's FY26 operating margin was 21.0%, against a 4-year range of 14.0% to 21.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 22.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Corona Remedies story? The main question: the share price moved +75.1% in a year while yearly earnings per share moved +23.9%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Corona Remedies a stock worth studying right now? What the numbers show: Corona Remedies Ltd's share price has risen faster than its earnings: +75.1% in a year, against +23.9% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Corona Remedies share price forecast for 2026? What management itself guided: FY27 organic revenue growth 15.0% and profit growth 20.0%. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.